Clinical Trial Results: Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery. [Phase 4]

View source ↗

Summary

Phase 4 trial comparing intravenous bezlotoxumab to placebo for reducing morbidity and mortality in fulminant Clostridioides difficile colitis requiring surgery…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Colitis

Drugs mentioned

• Bezlotoxumab (bezlotoxumab)

Snippet

Sponsor: Ohio State University | Conditions: Clostridia Difficile Colitis, Clostridium; Sepsis | Phase 4 | Status: TERMINATED | Results posted: 2026-06-18